. Author manuscript; available in PMC: 2015 Mar 1.

Published in final edited form as: J Allergy Clin Immunol. 2013 Nov 23;133(3):723–728.e3. doi: 10.1016/j.jaci.2013.09.037

Table I.

Baseline demographics of the CAMP and LOCCS populations.

N=808	CAMP (n=581)	LOCCS (n=228)
Mean [SD] or Percent (n)

Age in years [SD] (range)	8.9 [2.1] (5.2−13.2)	40.8 (14.1) (15−76)

Treatment group
Budesonide (ICS)	172 (30%)	76 (33%) Fluticasone (ICS)
Nedocromil	171 (29%)	83 (36%) Fluticasone/salmeterol
Placebo	238 (41%)	69 (30%) Montelukast

Gender,
Male	347 (60%)	85 (37%)
Female	243 (40%)	143 (63%)

PreFEV₁ at follow up,	1.91 [0.53]	2.89 [0.78]

Bronchodilator Response at follow up	0.097 [0.081]	0.065 [ 0.068]

FEV₁ percent predicted at follow up	95.68% [13.56%]	88% [16.7%]